SCHEMBL1711093

SCHEMBL1711093

Cc1ccc(CN(c2ccc(C(=O)N3CCN(c4ccccc4)CC3)cc2)S(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.71
HPGD P15428 2/20 0.70
KMT2A Q03164 1/20 0.70
CNR2 P34972 3/20 0.63
RAB9A P51151 1/20 0.62
HTT P42858 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
PTGES O14684 3/20 0.59
ALOX5 P09917 2/20 0.59
NPSR1 Q6W5P4 1/20 0.57
CNR1 P21554 2/20 0.55
GAA P10253 1/20 0.55
MAPT P10636 2/20 0.55
MAPK1 P28482 1/20 0.55
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL303907 0.96 LMNA (0.65) LMNAHPGDKMT2ACNR2RAB9A
SCHEMBL303307 0.93 LMNA (0.71) LMNAHPGDKMT2ACNR2HTT
SCHEMBL3282269 0.90 LMNA (0.68) LMNAHPGDKMT2ACNR2RAB9A
SCHEMBL302271 0.90 LMNA (0.68) LMNAHPGDKMT2ACNR2HTT
SCHEMBL302112 0.89 LMNA (0.65) LMNAHPGDKMT2ACNR2RAB9A
SCHEMBL302427 0.89 KMT2A (0.68) LMNAHPGDKMT2ACNR2RAB9A
SCHEMBL302434 0.87 KMT2A (0.66) LMNAHPGDKMT2ACNR2RAB9A
SCHEMBL1711080 0.87 LMNA (0.64) LMNAHPGDKMT2ACNR2RAB9A
SCHEMBL302243 0.86 LMNA (0.62) LMNAHPGDKMT2AHTTSMN1; SMN2
SCHEMBL1710747 0.86 LMNA (0.59) LMNAHPGDKMT2ARAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 LMNA 1683/4885HPGD 3739/4885KMT2A 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.